Rapid synthesis of oxytocin on the solid phase using active esters

Solid-phase synthesis of oxytocin using iodotrichlorosilane as Boc deprotecting agent

Deprotection of the tert-butoxycarbonyl group during solid-phase synthesis of peptides can be conveniently and efficiently carried out using a neutral reagent, silicon tetrachloride/sodium iodide (iodotrichlorosilane). This simple and rapid method has been advantageously employed during the solid-phase synthesis of the pituitary hormone, oxytocin.

Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids

9-Fluorenylmethoxycarbonyl (Fmoc) amino acids were first used for solid phase peptide synthesis a little more than a decade ago. Since that time, Fmoc solid phase peptide synthesis methodology has been greatly enhanced by the introduction of a variety of solid supports, linkages, and side chain protecting groups, as well as by increased understanding of solvation conditions. These advances have led to many impressive syntheses, such as those of biologically active and isotopically labeled peptides and small proteins. The great variety of conditions under which Fmoc solid phase peptide synthesis may be carried out represents a truly "orthogonal" scheme, and thus offers many unique opportunities for bioorganic chemistry.

Active esters in solid-phase peptide synthesis

Incorporation of single amino acid residues into peptide chains built on insoluble polymeric supports a priori appeared promising: the use of isolated, well defined (and potentially commercially available) reactive intermediates were expected to reduce the extent of undesired side reactions. In spite of these expectations active esters were only infrequently used in solid-phase peptide synthesis, mainly because the reaction rates achieved with them were insufficient for rapid chain-lengthening that became possible with automated instruments. In recent years, however, a certain revival of the active ester principle can be noted. This is the consequence of two factors: the application of highly reactive esters and the discovery of efficient catalysts of the ester-aminolysis reaction. The mechanism of catalysis and its explantation for further improvements are also discussed.

Synthesis and biological studies of dermorphin and its analogs substituted at positions 5 and 7

Dermorphin and seven of its analogs substituted at positions 5 and/or 7, have been synthesized by the solid phase method employing mainly 9-fluorenylmethyloxycarbonylamino acid trichlorophenyl esters in presence of l-hydroxybenzotriazole, the solid support being the Merrifield resin. Among the analogs synthesized, the most interesting is [Tyr7]dermorphin. It is one of the most potent dermorphin analogs reported so far. Compared to the natural peptide, it is about two times more potent in the GPI (in vitro) and nearly 1.4 times more potent in its analgesic activity in mice by the hot plate test (in vivo). Further, its antidiarrhoeal activity in mice (in vivo) is comparable to that of dermorphin. On the other hand, [Thr7]dermorphin is almost as potent as dermorphin.

Solid-phase peptide synthesis using tert.-butyloxycarbonylamino acid pentafluorophenyl esters

Boc-amino acid pentafluorophenyl esters have been successfully used in solid-phase peptide synthesis. The coupling rates and the purity of the products are comparable to those with the symmetrical anhydrides. These active esters require modified Merrifield resin, polar medium for coupling and in some cases, base catalysis.